LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Accueil・Liste d'Actions・Editas Medicine Inc

Editas Medicine Inc

Fermé

SecteurSoins de santé

2.47 -7.14

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.46

Max

2.67

Chiffres clés
By Trading Economics
Revenu	-19M -25M
Ventes	-22M 2.8M
BPA	-0.26
Marge bénéficiaire	-882.444
Employés	87
EBITDA	-19M -25M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+141.29% upside

Dividendes
By Dow Jones
Prochains Résultats	10 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	219M 513M
Ouverture précédente	9.61
Clôture précédente	2.47

Sentiment de l'Actualité

By Acuity

75%

25%

303 / 344 Classement par Healthcare

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juin 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 juin 2026, 23:45 UTC

Acquisitions, Fusions, Rachats

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 juin 2026, 23:43 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 juin 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 juin 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 juin 2026, 20:51 UTC

Résultats

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 juin 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 juin 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 juin 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 juin 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 juin 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 juin 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 juin 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 juin 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 juin 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 juin 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 juin 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juin 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 juin 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

141.29% hausse

Prévisions sur 12 Mois

Moyen 6.37 USD 141.29%

Haut 15 USD

Bas 4 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

303 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.